Region:Middle East
Author(s):Rebecca
Product Code:KRAD4287
Pages:83
Published On:December 2025
By Sequencing Type:The segmentation of the market by sequencing type includes various methods that cater to different research and clinical needs. Whole-Genome RNA Sequencing (RNA-seq) is gaining traction due to its comprehensive analysis capabilities, while Whole-Transcriptome Sequencing is favored for its ability to capture the entire transcriptome. Targeted RNA Sequencing Panels are popular for specific gene or pathway studies, particularly in oncology and inherited disease panels, and Single-Cell RNA Sequencing (scRNA-seq) is increasingly used in advanced research centers for detailed cellular and immune profiling. Other RNA sequencing methods, such as long-read and isoform sequencing, are also emerging as valuable tools in genomics for more accurate transcript isoform resolution and structural variant characterization, often relying on platforms from Pacific Biosciences and Oxford Nanopore.
By End-User:The end-user segmentation highlights the diverse applications of RNA sequencing across various sectors. Academic and research institutes are the largest consumers, driven by national programs at institutions such as KFSHRC, KAUST, and major universities, which run large-scale genomics and transcriptomics projects. Hospitals and oncology centers utilize RNA sequencing for cancer genomics, inherited disease diagnostics, and treatment planning, while clinical and reference laboratories support a wide range of testing services including NGS-based diagnostic panels. Pharmaceutical and biotechnology companies, including regional biotech start-ups encouraged by Saudi Arabia’s biotechnology strategy, leverage RNA sequencing for biomarker discovery and drug development, and government and public health agencies increasingly apply RNA sequencing to infectious disease surveillance and population health studies.
The Saudi Arabia NGS Based RNA Sequencing Market is characterized by a dynamic mix of regional and international players. Leading participants such as Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., F. Hoffmann-La Roche Ltd (Roche Sequencing), BGI Genomics Co., Ltd., Agilent Technologies, Inc., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies plc, Danaher Corporation (Beckman Coulter, Cytiva, Integrated DNA Technologies), Eurofins Scientific SE, Revvity, Inc. (formerly part of PerkinElmer), 10x Genomics, Inc., Twist Bioscience Corporation, Pillar Biosciences, Inc., and local and regional sequencing service providers (e.g., Saudi-based clinical and research genomics labs) contribute to innovation, geographic expansion, and service delivery in this space. These companies typically participate through a mix of direct sales, distributor partnerships, and collaborations with leading Saudi institutions on projects in oncology, rare disease genomics, and large-scale population studies, while local laboratories provide sequencing-as-a-service to hospitals and research groups.
The future of the NGS-based RNA sequencing market in Saudi Arabia appears promising, driven by technological advancements and increased government support. In future, the integration of artificial intelligence in genomic research is expected to enhance data analysis capabilities, leading to more accurate results. Additionally, the expansion of healthcare infrastructure, including new genomic research centers, will facilitate greater access to NGS technologies, ultimately improving patient care and fostering innovation in personalized medicine.
| Segment | Sub-Segments |
|---|---|
| By Sequencing Type | Whole-Genome RNA Sequencing (RNA-seq) Whole-Transcriptome Sequencing Targeted RNA Sequencing Panels Single-Cell RNA Sequencing (scRNA-seq) Other RNA Sequencing Methods (e.g., long-read, isoform sequencing) |
| By End-User | Academic and Research Institutes (e.g., KFSHRC, KAUST, universities) Hospitals and Oncology Centers Clinical and Reference Laboratories Pharmaceutical and Biotechnology Companies Government and Public Health Agencies |
| By Application | Oncology and Cancer Genomics Rare and Inherited Disease Diagnostics Transcriptome Profiling and Gene Expression Studies Pharmacogenomics and Precision Medicine Other Research and Translational Applications (e.g., immunology, infectious disease) |
| By Technology Platform | Sequencing by Synthesis (Illumina Platforms) Ion Semiconductor Sequencing (Ion Torrent) Single-Molecule Real-Time (SMRT) Sequencing Nanopore Sequencing Technology Other NGS Technologies |
| By Sample Type | Blood and Plasma (including cell-free RNA) Solid Tissue Biopsies Formalin-Fixed Paraffin-Embedded (FFPE) Samples Other Sample Types (e.g., saliva, bone marrow, swabs) |
| By Region | Central Region (including Riyadh) Eastern Region (including Dammam and Dhahran) Western Region (including Jeddah and Makkah) Southern and Northern Regions |
| By Funding Source | Government Grants and National Programs (e.g., Saudi Human Genome Program) Institutional and Academic Research Funding Private Investments and Venture Funding Industry-Sponsored Research and Collaborations |
| Scope Item/Segment | Sample Size | Target Respondent Profiles |
|---|---|---|
| Clinical Diagnostics Laboratories | 120 | Laboratory Directors, Clinical Pathologists |
| Biotechnology Firms | 90 | Product Managers, R&D Scientists |
| Academic Research Institutions | 80 | Principal Investigators, Core Facility Managers |
| Healthcare Providers | 100 | Chief Medical Officers, Genetic Counselors |
| Government Health Agencies | 60 | Policy Makers, Health Program Managers |
The Saudi Arabia NGS Based RNA Sequencing Market is valued at approximately USD 25 million, with an estimated revenue of USD 24.6 million generated in 2024. This growth is driven by national genomics initiatives and increased adoption of precision medicine.
What makes us stand out is that our consultants follow Robust, Refine and Result (RRR) methodology. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents' facts and opinions, and Result for presenting data with story.
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.